Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer
Status:
Withdrawn
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
This phase II clinical trial is studying how well giving combination chemotherapy and
bevacizumab with or without RO4929097 works in treating patients with metastatic colorectal
cancer. Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, and
fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the
cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can
block tumor growth in different ways. Some block the ability of tumor cells to grow and
spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. It is not yet known whether combination chemotherapy and bevacizumab is more
effective with RO4929097 in treating patients with colorectal cancer.